Redefining preclinical digestion & gut microbiome research

Why?

Whenever you find yourself on the side of the majority, it is time to reform (or pause and reflect).

Mark Twain

Since the 90’s, traditional in vitro gastrointestinal research methods have stagnated. Especially for gut microbiome research, such models rely on slow, labour-intensive and expensive tools with limited interpretability. As a result, you have to compromise on either the scope of the study (i.e. number of products tested) or on the robustness and significance of it (addressing interindividual variability within a population). At Cryptobiotix, we think different: why not combine quality and quantity? We thrive on redefining established processes, both in the lab and in thinking. Challenge us with your research question and let us customise the most suitable path forward in your early and late R&D stages of product development.

Shift from in vitro gastrointestinal studies to high-throughput & biorelevant ex vivo studies.
Move away from time-consuming and cost-intensive simulations, towards high-throughput & biorelevant data generation.

How?

There are three key aspects in how we work:

  1. Increase biorelevance
  2. Increase throughput by miniaturisation
  3. Clarify the key findings through advanced data interpretation

What?

Cryptobiotix is a CRO in the gastrointestinal field that provides state-of-the-art preclinical research services using the SIFR® (“cipher”) and D-SIFR® (“decipher”) technologies. They combine in vitro and ex vivo approaches to enable you to investigate more products, in a statistically robust design that considers biological variation.

We answer research questions pertaining to:

  • upper gastrointestinal digestion and absorption
  • interplay with the gut microbiota and host-microbiome interactions

We use those biorelevant, high-throughput models to generate an unprecedented amount of data, that we analyse, interpret and report.


Your applications

Research objective

  • Screening & ranking of candidates before clinical trials

  • In-depth characterisation of promising lead product

  • Generation and protection of IP

  • Support your claims

Product type

Functional food

Therapeutics

Target group

Investigate the impact of your products across a wide range of human and animal hosts, healthy or diseased.

Our technologies: SIFR® & D-SIFR®

Relying on the latest published insights in digestion and gut microbiome research, the SIFR and D-SIFR technologies address various questions pertaining to digestion and fermentation. Complementing high biorelevance with operational standardisation, this high-throughput technology allows you to allocate your preclinical budget optimally from early candidate screening to in-depth lead product characterisation.

Simulate digestion absorption and interplay with the gut microbiota with the D-SIFR.

Don’t press the red button!